13G Filing: Sabby Capital and Moleculin Biotech Inc (MBRX)

Page 5 of 10 – SEC Filing

(e).
CUSIP No.:60855D101

Item 3.
If This Statement is filed pursuant to Section 240.13d-1(b) or
240.13d-2(b), or (c), check whether the person filing is a

(a)
[_]
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)
[_]
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)
[_]
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d)
[_]
Investment company registered under section 8 of the Investment Company Act of
1940 (15 U.S.C. 80a-8).

(e)
[_]
An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);

(f)
[_]
An employee benefit plan or endowment fund in accordance with Section 240.13d-
1(b)(1)(ii)(F);

(g)
[_]
A parent holding company or control person in accordance with Section 240.13d-
1(b)(1)(ii)(G);

(h)
[_]
A savings association as defined in Section 3(b) of the Federal Deposit
Insurance Act (12 U.S.C.1813);

(i)
[_]
A church plan that is excluded from the definition of an investment
company under section 3(c)(14) of the Investment Company Act of 1940
(15 U.S.C. 80a-3);

(j)
[_]
A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);

(k)
[_]
Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as
a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: